Idorsia Ltd

OTCPK:IDRS.F Stock Report

Market Cap: US$178.3m

Idorsia Valuation

Is IDRS.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDRS.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IDRS.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IDRS.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDRS.F?

Key metric: As IDRS.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IDRS.F. This is calculated by dividing IDRS.F's market cap by their current revenue.
What is IDRS.F's PS Ratio?
PS Ratio2.1x
SalesCHF 74.12m
Market CapCHF 158.01m

Price to Sales Ratio vs Peers

How does IDRS.F's PS Ratio compare to its peers?

The above table shows the PS ratio for IDRS.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.9x
VSTM Verastem
17.4x59.3%US$178.0m
CRBU Caribou Biosciences
15.9x66.7%US$182.9m
YMTX Yumanity Therapeutics
29.7xn/aUS$143.6m
TLSI TriSalus Life Sciences
4.6x33.6%US$138.3m
IDRS.F Idorsia
2.1x53.8%US$158.0m

Price-To-Sales vs Peers: IDRS.F is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (12.7x).

Price to Sales Ratio vs Industry

How does IDRS.F's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.4x21.4%
IDRS.F Idorsia
 2.1x53.8%US$178.30m
GILD Gilead Sciences
4x2.4%US$112.40b
BIIB Biogen
2.4x1.3%US$23.01b
IDRS.F 2.1xIndustry Avg. 9.4xNo. of Companies128PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.4x28.3%
IDRS.F Idorsia
 2.1x15.1%US$178.30m
No more companies

Price-To-Sales vs Industry: IDRS.F is good value based on its Price-To-Sales Ratio (2.1x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is IDRS.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDRS.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IDRS.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDRS.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.84
US$1.85
+120.4%
44.5%US$3.01US$1.16n/a3
Nov ’25US$1.09
US$1.84
+69.2%
44.5%US$3.00US$1.15n/a3
Oct ’25n/a
US$2.09
0%
31.9%US$3.06US$1.18n/a5
Sep ’25US$2.59
US$2.09
-19.2%
31.9%US$3.06US$1.18n/a5
Aug ’25n/a
US$2.01
0%
29.6%US$2.98US$1.14n/a6
Jul ’25n/a
US$1.89
0%
31.1%US$2.90US$1.11n/a8
Jun ’25US$2.25
US$1.85
-17.8%
31.1%US$2.84US$1.09n/a8
May ’25US$1.95
US$1.91
-2.1%
32.0%US$2.88US$1.11n/a8
Apr ’25US$2.64
US$2.34
-11.5%
41.1%US$4.45US$1.11n/a8
Mar ’25n/a
US$2.34
0%
41.7%US$4.53US$1.13n/a8
Feb ’25US$1.68
US$2.36
+40.6%
41.7%US$4.57US$1.14n/a8
Jan ’25US$2.45
US$2.36
-3.6%
41.7%US$4.57US$1.14n/a8
Dec ’24US$2.47
US$2.98
+20.5%
64.5%US$7.35US$1.13n/a8
Nov ’24US$1.85
US$4.71
+154.4%
79.2%US$13.31US$1.11US$1.098
Oct ’24US$2.79
US$7.10
+154.6%
36.3%US$13.37US$4.46n/a8
Sep ’24US$5.56
US$7.15
+28.6%
35.1%US$13.67US$4.56US$2.599
Aug ’24US$7.65
US$6.66
-13.0%
13.1%US$7.48US$4.83n/a7
Jul ’24US$7.50
US$12.21
+62.8%
62.8%US$33.58US$6.72n/a10
Jun ’24US$8.65
US$15.41
+78.1%
57.0%US$33.69US$7.86US$2.259
May ’24US$9.55
US$15.10
+58.1%
56.6%US$33.66US$6.73US$1.9510
Apr ’24US$11.05
US$16.19
+46.5%
39.7%US$31.89US$9.57US$2.6411
Mar ’24US$13.60
US$16.19
+19.1%
39.7%US$31.89US$9.57n/a11
Feb ’24US$16.73
US$19.18
+14.7%
39.2%US$39.62US$11.00US$1.6811
Jan ’24US$14.69
US$19.46
+32.5%
39.1%US$38.55US$10.71US$2.4511
Dec ’23US$14.81
US$20.89
+41.1%
35.0%US$38.27US$10.63US$2.4711
Nov ’23US$15.75
US$19.98
+26.9%
34.8%US$36.50US$10.14US$1.8510

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

7D

6.8%

1Y

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

7D

6.1%

1Y

14.8%